184 related articles for article (PubMed ID: 31652551)
1. The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing
Ramirez-Peña E; Arnold J; Shivakumar V; Joseph R; Vidhya Vijay G; den Hollander P; Bhangre N; Allegakoen P; Prasad R; Conley Z; Matés JM; Márquez J; Chang JT; Vasaikar S; Soundararajan R; Sreekumar A; Mani SA
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31652551
[TBL] [Abstract][Full Text] [Related]
2. GLS2 is protumorigenic in breast cancers.
Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer.
Li HJ; Li X; Pang H; Pan JJ; Xie XJ; Chen W
Jpn J Clin Oncol; 2015 Nov; 45(11):1055-63. PubMed ID: 26373319
[TBL] [Abstract][Full Text] [Related]
4. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis.
Zhang C; Liu J; Zhao Y; Yue X; Zhu Y; Wang X; Wu H; Blanco F; Li S; Bhanot G; Haffty BG; Hu W; Feng Z
Elife; 2016 Jan; 5():e10727. PubMed ID: 26751560
[TBL] [Abstract][Full Text] [Related]
5. Two Faces of Glutaminase GLS2 in Carcinogenesis.
Buczkowska J; Szeliga M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067269
[TBL] [Abstract][Full Text] [Related]
6. Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells.
Kuo TC; Chen CK; Hua KT; Yu P; Lee WJ; Chen MW; Jeng YM; Chien MH; Kuo KT; Hsiao M; Kuo ML
Cancer Lett; 2016 Dec; 383(2):282-294. PubMed ID: 27725225
[TBL] [Abstract][Full Text] [Related]
7. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.
Suzuki S; Tanaka T; Poyurovsky MV; Nagano H; Mayama T; Ohkubo S; Lokshin M; Hosokawa H; Nakayama T; Suzuki Y; Sugano S; Sato E; Nagao T; Yokote K; Tatsuno I; Prives C
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7461-6. PubMed ID: 20351271
[TBL] [Abstract][Full Text] [Related]
8. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
[TBL] [Abstract][Full Text] [Related]
9. Structure and activation mechanism of the human liver-type glutaminase GLS2.
Ferreira IM; Quesñay JEN; Bastos AC; Rodrigues CT; Vollmar M; Krojer T; Strain-Damerell C; Burgess-Brown NA; von Delft F; Yue WW; Dias SM; Ambrosio AL
Biochimie; 2021 Jun; 185():96-104. PubMed ID: 33746066
[TBL] [Abstract][Full Text] [Related]
10. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition induces similar metabolic alterations in two independent breast cancer cell lines.
Kondaveeti Y; Guttilla Reed IK; White BA
Cancer Lett; 2015 Aug; 364(1):44-58. PubMed ID: 25917568
[TBL] [Abstract][Full Text] [Related]
12. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
13. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation.
Xiang L; Xie G; Liu C; Zhou J; Chen J; Yu S; Li J; Pang X; Shi H; Liang H
Biochim Biophys Acta; 2013 Dec; 1833(12):2996-3005. PubMed ID: 23954443
[TBL] [Abstract][Full Text] [Related]
14. EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition.
Karvelsson ST; Sigurdsson A; Seip K; Grinde MT; Wang Q; Johannsson F; Mælandsmo GM; Moestue SA; Rolfsson O; Halldorsson S
Mol Cancer Res; 2021 Sep; 19(9):1546-1558. PubMed ID: 34088869
[TBL] [Abstract][Full Text] [Related]
15. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
[TBL] [Abstract][Full Text] [Related]
16. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.
Hu W; Zhang C; Wu R; Sun Y; Levine A; Feng Z
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7455-60. PubMed ID: 20378837
[TBL] [Abstract][Full Text] [Related]
17. The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers.
Basheer HA; Elsalem L; Salem A; Tailor A; Hunter K; Afarinkia K
Curr Cancer Drug Targets; 2022; 22(2):169-179. PubMed ID: 34951574
[TBL] [Abstract][Full Text] [Related]
18. FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer.
Børretzen A; Gravdal K; Haukaas SA; Beisland C; Akslen LA; Halvorsen OJ
J Pathol Clin Res; 2019 Oct; 5(4):272-286. PubMed ID: 31464093
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral bidirectional transitions between epithelial and mesenchymal cells in triple-negative breast cancer.
Yamamoto M; Sakane K; Tominaga K; Gotoh N; Niwa T; Kikuchi Y; Tada K; Goshima N; Semba K; Inoue JI
Cancer Sci; 2017 Jun; 108(6):1210-1222. PubMed ID: 28371195
[TBL] [Abstract][Full Text] [Related]
20. OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Qi XK; Han HQ; Zhang HJ; Xu M; Li L; Chen L; Xiang T; Feng QS; Kang T; Qian CN; Cai MY; Tao Q; Zeng YX; Feng L
Theranostics; 2018; 8(8):2202-2216. PubMed ID: 29721073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
